• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

CCDC6,与不同原癌基因融合的基因产物,作为一种潜在的化疗靶点。

CCDC6, a gene product in fusion with different protoncogenes, as a potential chemotherapeutic target.

机构信息

School of Bioengineering and Biosciences, Lovely Professional University, Phagwara, Punjab 144411, India.

School of Pharmaceutical Sciences, Lovely Professional University, Phagwara, Punjab 144411, India.

出版信息

Cancer Biomark. 2019;24(4):383-393. doi: 10.3233/CBM-181601.

DOI:10.3233/CBM-181601
PMID:30909182
Abstract

Cancer, a deadly disease is characterized by abnormal cell growth with the potential to invade to other parts of the body. Most cancers start due to changes at gene level that happen over a person's lifetime when DNA repair system becomes faulty. CCDC6, one of the players in DNA repair system acts as a tumor suppressor gene. It was originally identified in chimeric genes caused by chromosomal translocation involving RET proto-oncogene in some thyroid tumors. Different fusion chimers with different proto-oncogenes like RET are known for CCDC6 which hampered its function. Further, CCDC6 is recognized as a pro-apoptotic phosphoprotein, which is an ATM substrate responsive to genotoxic stress. In this article, we reviewed the published literature to characterize CCDC6 fusions with proto-oncogenes and the role of natural phytochemicals which can potentially alter CCDC6 activity and thus can prove beneficial for cancer patients.

摘要

癌症是一种致命的疾病,其特征是异常细胞生长,并有可能侵入身体的其他部位。大多数癌症是由于一个人一生中基因水平的变化引起的,当 DNA 修复系统出现故障时,就会发生这种变化。CCDC6 是 DNA 修复系统的参与者之一,作为一种肿瘤抑制基因。它最初是在一些甲状腺肿瘤中涉及 RET 原癌基因的染色体易位引起的嵌合基因中被发现的。不同的融合嵌合体与不同的原癌基因如 RET 有关,这阻碍了 CCDC6 的功能。此外,CCDC6 被认为是一种促凋亡的磷酸蛋白,是 ATM 底物对遗传毒性应激的反应。在本文中,我们回顾了已发表的文献,以描述与原癌基因融合的 CCDC6 及其作用,以及天然植物化学物质可能改变 CCDC6 活性的作用,从而可能对癌症患者有益。

相似文献

1
CCDC6, a gene product in fusion with different protoncogenes, as a potential chemotherapeutic target.CCDC6,与不同原癌基因融合的基因产物,作为一种潜在的化疗靶点。
Cancer Biomark. 2019;24(4):383-393. doi: 10.3233/CBM-181601.
2
Antitumor activities of the targeted multi-tyrosine kinase inhibitor lenvatinib (E7080) against RET gene fusion-driven tumor models.针对 RET 基因融合驱动肿瘤模型的靶向多酪氨酸激酶抑制剂仑伐替尼(E7080)的抗肿瘤活性。
Cancer Lett. 2013 Oct 28;340(1):97-103. doi: 10.1016/j.canlet.2013.07.007. Epub 2013 Jul 12.
3
Loss of CCDC6, the first identified RET partner gene, affects pH2AX S139 levels and accelerates mitotic entry upon DNA damage.CCDC6 的缺失,第一个被鉴定的 RET 伙伴基因,影响 pH2AX S139 水平,并在 DNA 损伤时加速有丝分裂的进入。
PLoS One. 2012;7(5):e36177. doi: 10.1371/journal.pone.0036177. Epub 2012 May 24.
4
Identification of sumoylation sites in CCDC6, the first identified RET partner gene in papillary thyroid carcinoma, uncovers a mode of regulating CCDC6 function on CREB1 transcriptional activity.鉴定在甲状腺乳头状癌中首次被鉴定为 RET 伙伴基因的 CCDC6 的 SUMO 化位点,揭示了一种调节 CCDC6 功能对 CREB1 转录活性的方式。
PLoS One. 2012;7(11):e49298. doi: 10.1371/journal.pone.0049298. Epub 2012 Nov 7.
5
CCDC6: the identity of a protein known to be partner in fusion.CCDC6:一种已知的融合伙伴蛋白的身份。
Int J Cancer. 2018 Apr 1;142(7):1300-1308. doi: 10.1002/ijc.31106. Epub 2017 Oct 26.
6
Ccdc6 knock-in mice develop thyroid hyperplasia associated to an enhanced CREB1 activity.Ccdc6基因敲入小鼠发生与CREB1活性增强相关的甲状腺增生。
Oncotarget. 2015 Jun 20;6(17):15628-38. doi: 10.18632/oncotarget.3858.
7
USP7 inhibitors, downregulating CCDC6, sensitize lung neuroendocrine cancer cells to PARP-inhibitor drugs.USP7抑制剂通过下调CCDC6,使肺神经内分泌癌细胞对PARP抑制剂药物敏感。
Lung Cancer. 2017 May;107:41-49. doi: 10.1016/j.lungcan.2016.06.015. Epub 2016 Jun 17.
8
Driver Fusions and Their Implications in the Development and Treatment of Human Cancers.驱动融合及其在人类癌症发生和治疗中的意义。
Cell Rep. 2018 Apr 3;23(1):227-238.e3. doi: 10.1016/j.celrep.2018.03.050.
9
The rationale for druggability of CCDC6-tyrosine kinase fusions in lung cancer.肺癌中 CCDC6-酪氨酸激酶融合物可成药性的基本原理。
Mol Cancer. 2018 Feb 19;17(1):46. doi: 10.1186/s12943-018-0799-8.
10
CCDC6 and USP7 expression levels suggest novel treatment options in high-grade urothelial bladder cancer.CCDC6 和 USP7 的表达水平提示了高级别尿路上皮膀胱癌的新治疗选择。
J Exp Clin Cancer Res. 2019 Feb 20;38(1):90. doi: 10.1186/s13046-019-1087-1.

引用本文的文献

1
Targeted therapy based on ubiquitin-specific proteases, signalling pathways and E3 ligases in non-small-cell lung cancer.基于泛素特异性蛋白酶、信号通路和E3连接酶的非小细胞肺癌靶向治疗
Front Oncol. 2023 Mar 9;13:1120828. doi: 10.3389/fonc.2023.1120828. eCollection 2023.
2
High expression of CCDC6 in relation to unfavorable outcome and immune cells infiltration in hepatobiliary carcinoma.CCDC6在肝胆癌中的高表达与不良预后及免疫细胞浸润的关系
J Cancer. 2022 Sep 21;13(12):3378-3395. doi: 10.7150/jca.76050. eCollection 2022.
3
Coiled-coil domain-containing 68 promotes non-small cell lung cancer cell proliferation .
含卷曲螺旋结构域蛋白68促进非小细胞肺癌细胞增殖。
Oncol Lett. 2020 Dec;20(6):356. doi: 10.3892/ol.2020.12220. Epub 2020 Oct 14.
4
NSCLC Mutated Isoforms of CCDC6 Affect the Intracellular Distribution of the Wild Type Protein Promoting Cisplatinum Resistance and PARP Inhibitors Sensitivity in Lung Cancer Cells.CCDC6的非小细胞肺癌突变异构体影响野生型蛋白的细胞内分布,促进肺癌细胞的顺铂耐药性和PARP抑制剂敏感性。
Cancers (Basel). 2019 Dec 21;12(1):44. doi: 10.3390/cancers12010044.